CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published, non RCT

The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients - A pilot study.

  • Year: 2016
  • Date: 2016
  • Author: Hanssens L
Source

Prostaglandins Leukot Essent Fatty Acids. 2016 May;108:45-50. doi: 10.1016/j.plefa.2016.03.014. Epub 2016 Mar 28.

Study design (if review, criteria of inclusion for studies)

Randomized controlled trial

Participants

Fifteen deltaF508-homozygous patients undergoing chronic azithromycin

Interventions

1 year of oral omega-3 supplementation; patients were randomized to receive omega-3 fish oil supplementation at a dose of 60 mg/Kg/day or placebo.

Outcome measures

Clinical status, exercise tolerance, inflammatory parameters, and erythrocyte fatty acid profile

Main results

In comparison with the previous year, in the supplemented group, the number of pulmonary exacerbations decreased at 12 months (1.7 vs. 3.0, p<0.01), as did the duration of antibiotic therapy (26.5 days vs. 60.0 days, p<0.025). Supplementation significantly increased the levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as early as <3 months of administration, with concomitant decreases in arachidonic acid (AA) levels.

Authors' conclusions

This pilot study suggests that long-term omega-3 supplementation offers several clinical benefits as to the number of exacerbations and duration of antibiotic therapy in CF patients.

Keywords: omega-3; Fish Oils; non pharmacological intervention - diet; Supplementation; essential fatty acids; Food; pharmacological_intervention;